DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Taiwan

Recruiting

Conditions: Psoriasis

First Posted Date: 2021-03-26

Last Posted Date: 2025-01-28

Lead Sponsor: AbbVie

Target Recruit Count: 240

Registration Number: NCT04818385

Locations: 🇨🇳
National Taiwan University Hospital - Hsinchu branch /ID# 238432, Hsinchu City, Taiwan
🇨🇳
Hualien Tzu Chi Hospital /ID# 238431, Hualien City, Taiwan
🇨🇳
Taipei Medical University Hospital /ID# 230018, Taipei City, Taiwan

and more 5 locations

Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid Leukemia

Completed

Conditions: Acute Myeloid Leukemia (AML)

First Posted Date: 2021-03-24

Last Posted Date: 2025-04-27

Lead Sponsor: AbbVie

Target Recruit Count: 424

Registration Number: NCT04813263

Locations: 🇯🇵
Odate Municipal General Hospital /ID# 258238, Odate-shi, Akita, Japan
🇯🇵
Yokohama City University Medical Center /ID# 248777, Yokohama shi, Kanagawa, Japan
🇯🇵
Kyoto University Hospital /ID# 244844, Kyoto-shi, Kyoto, Japan

and more 278 locations

Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function

Phase 1

Completed

Conditions: Renal Impairment
Renal Disease

Interventions: Drug: Venetoclax

First Posted Date: 2021-03-23

Last Posted Date: 2022-09-16

Lead Sponsor: AbbVie

Target Recruit Count: 12

Registration Number: NCT04810598

Locations: 🇺🇸
Orlando Clinical Research Ctr /ID# 224922, Orlando, Florida, United States
🇺🇸
Acpru /Id# 243398, Grayslake, Illinois, United States

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

Phase 1

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: ABBV-927
Drug: Budiglimab
Drug: modified FOLFIRINOX

First Posted Date: 2021-03-19

Last Posted Date: 2025-01-07

Lead Sponsor: AbbVie

Target Recruit Count: 40

Registration Number: NCT04807972

Locations: 🇺🇸
Johns Hopkins Hospital /ID# 226713, Baltimore, Maryland, United States
🇮🇱
The Chaim Sheba Medical Center /ID# 226812, Ramat Gan, Tel-Aviv, Israel
🇮🇱
Rambam Health Care Campus /ID# 229555, Haifa, H_efa, Israel

and more 12 locations

Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers

Phase 1

Terminated

Conditions: B-cell Lymphoma

Interventions: Drug: ABBV-623
Drug: ABBV-992

First Posted Date: 2021-03-18

Last Posted Date: 2023-02-03

Lead Sponsor: AbbVie

Target Recruit Count: 5

Registration Number: NCT04804254

Locations: 🇮🇱
The Chaim Sheba Medical Center /ID# 226754, Ramat Gan, Tel-Aviv, Israel
🇵🇷
Hospital del Centro Comprensivo de Cancer de la UPR /ID# 225646, San Juan, Puerto Rico
🇹🇷
Dokuz Eylul University Medical Faculty /ID# 226085, Izmir, Turkey

and more 2 locations

Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)

Phase 1

Completed

Conditions: Human Immunodeficiency Virus (HIV)

Interventions: Drug: Budigalimab
Drug: Placebo

First Posted Date: 2021-03-16

Last Posted Date: 2022-10-17

Lead Sponsor: AbbVie

Target Recruit Count: 33

Registration Number: NCT04799353

Locations: 🇺🇸
Central Texas Clinical Research /ID# 223937, Austin, Texas, United States
🇺🇸
Franco Felizarta, Md /Id# 223931, Bakersfield, California, United States
🇺🇸
Ruane Clinical Research Group /ID# 224496, Los Angeles, California, United States

and more 7 locations

Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting

Withdrawn

Conditions: Psoriasis

Interventions: Drug: Comparator 2
Biological: Comparator 1
Drug: Risankizumab

First Posted Date: 2021-03-16

Last Posted Date: 2022-12-09

Lead Sponsor: AbbVie

Registration Number: NCT04799990

Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of Care

Active, not recruiting

Conditions: Psoriasis

First Posted Date: 2021-03-03

Last Posted Date: 2025-01-15

Lead Sponsor: AbbVie

Target Recruit Count: 141

Registration Number: NCT04780516

Locations: 🇮🇱
Duplicate_Kaplan Medical Center /ID# 226569, Rehovot, HaMerkaz, Israel
🇮🇱
HaEmek Medical Center /ID# 251040, Afula, H_efa, Israel
🇮🇱
Maccabi /ID# 246679, Haifa, H_efa, Israel

and more 8 locations

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

Phase 3

Recruiting

Conditions: Depression
Bipolar I Disorder

Interventions: Drug: Placebo
Drug: Cariprazine

First Posted Date: 2021-03-02

Last Posted Date: 2025-04-09

Lead Sponsor: AbbVie

Target Recruit Count: 380

Registration Number: NCT04777357

Locations: 🇺🇸
Pillar Clinical Research /ID# 226504, Bentonville, Arkansas, United States
🇺🇸
Advanced Research Center /ID# 227073, Anaheim, California, United States
🇺🇸
Care Access Research /ID# 226316, Beverly Hills, California, United States

and more 67 locations

Open-label Trial in Parkinson's Disease (PD)

Phase 3

Active, not recruiting

Conditions: Parkinson Disease

Interventions: Drug: Tavapadon

First Posted Date: 2021-02-18

Last Posted Date: 2025-03-26

Lead Sponsor: AbbVie

Target Recruit Count: 992

Registration Number: NCT04760769

Locations: 🇺🇸
Pheonix, Arizona, Phoenix, Arizona, United States
🇺🇸
Reseda, California, Reseda, California, United States
🇺🇸
Naples, Florida, Naples, Florida, United States

and more 127 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy